U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced plans for a nationwide advertising campaign encouraging Americans to adopt health wearables, such as heart rate and continuous glucose monitors. The initiative is part of the department’s broader “Making America Healthy Again” (MAHA) agenda.
Speaking before the House Energy and Commerce Committee’s Health Subcommittee, Kennedy emphasized the importance of personal health data. “My vision is that every American is wearing a wearable within four years,” he said. “It’s a way for people to take control of their health—seeing real-time impacts of food on glucose levels and heart rate.”
The announcement boosted shares of glucose-monitoring device makers. Dexcom (NASDAQ:DXCM) surged 10%, while Abbott gained 3.6% in afternoon trading.
Kennedy, a longtime advocate for preventive health and a critic of overreliance on pharmaceuticals, pointed to the cost-effectiveness of wearables compared to popular weight-loss drugs. “Ozempic costs $1,300 a month. If you can achieve similar results with an $80 wearable, that’s a better deal for Americans,” he noted. While he has criticized drugs like Novo Nordisk’s Ozempic, Kennedy supports their use for patients with morbid obesity or diabetes, when combined with exercise.
The campaign, which he described as one of the largest in HHS history, aims to shift the focus from reactive to proactive health management. Kennedy also hinted at exploring ways to subsidize wearables to make them more accessible.
J.P. Morgan analyst Robbie Marcus cautioned against assuming immediate changes in Medicare or insurance coverage for proactive monitoring, saying it’s too early to predict policy shifts.
The wearable tech market stands to benefit from this government push, as health monitoring tools become more mainstream in personal wellness strategies.


Trump’s Iraq Envoy Mark Savaya Ousted Amid U.S.-Iraq Tensions Over Iran Influence
Putin Envoy Kirill Dmitriev to Visit Miami for Talks With Trump Administration Officials
Starmer’s China Visit Highlights Western Balancing Act Amid U.S.-China Rivalry
Japan Election Poll Signals Landslide Win for Sanae Takaichi, Raising Fiscal Policy Concerns
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement
Rafah Border Crossing to Reopen for Palestinians as Israel Coordinates with Egypt and EU
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Keir Starmer Urges Prince Andrew to Testify in U.S. Epstein Investigation
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Minnesota Judge Rejects Bid to Halt Trump Immigration Enforcement in Minneapolis
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
U.S.–Venezuela Relations Show Signs of Thaw as Top Envoy Visits Caracas 



